We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-14.16%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$945M
AUM Growth
+$449M
Cap. Flow
+$500M
Cap. Flow %
52.91%
Top 10 Hldgs %
96.22%
Holding
18
New
4
Increased
3
Reduced
10
Closed
1

Top Buys

Rank Stock Value
1
SPRO icon
Spero Therapeutics
SPRO
+$30.2M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$7.1M
3
BPMC
Blueprint Medicines
BPMC
+$5.44M
4
ACIU icon
AC Immune
ACIU
+$3.33M
5
GMAB icon
Genmab
GMAB
+$1.81M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$6.8M
2
PVLA
Palvella Therapeutics
PVLA
+$5.41M
3
MOR
MorphoSys AG American Depositary Shares
MOR
+$3.04M
4
ANAB icon
AnaptysBio
ANAB
+$2.04M
5
QURE icon
uniQure
QURE
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 23.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$446M 47.19%
4,000,000
+2,000,000
+100% +$224M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.9B
$255M 26.96%
+1,700,000
New +$256M
SPRO icon
3
Spero Therapeutics
SPRO
$73M
$50.2M 5.31%
4,497,142
+2,554,061
+131% +$30.2M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$35.8M 3.79%
385,727
+70,698
+22% +$5.44M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$24.7M 2.62%
1,374,776
-79,910
-5% -$1.65M
QURE icon
6
uniQure
QURE
$3.22B
$23.2M 2.46%
631,060
-48,560
-7% -$1.99M
ARWR icon
7
Arrowhead Research
ARWR
$12.4B
$22.5M 2.39%
523,415
-39,876
-7% -$1.72M
ANAB icon
8
AnaptysBio
ANAB
$1.68B
$21.8M 2.31%
1,477,652
-113,081
-7% -$2.04M
NGM
9
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$16.2M 1.72%
1,018,334
-76,850
-7% -$1.4M
RGNX icon
10
Regenxbio
RGNX
$708M
$14.1M 1.49%
510,760
-42,693
-8% -$1.39M
PRQR icon
11
ProQR Therapeutics
PRQR
$265M
$10.9M 1.16%
2,281,966
-119,604
-5% -$626K
PVLA
12
Palvella Therapeutics
PVLA
$2.27B
$7.61M 0.81%
45,944
-23,750
-34% -$5.41M
DNTH icon
13
Dianthus Therapeutics
DNTH
$6.09B
$6.52M 0.69%
+59,914
New +$7.1M
LKFT
14
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$4.62M 0.49%
32,534
-11,700
-26% -$1.95M
ACIU icon
15
AC Immune
ACIU
$240M
$2.26M 0.24%
+463,575
New +$3.33M
ARGX icon
16
argenx
ARGX
$54.1B
$1.97M 0.21%
7,500
-28,300
-79% -$6.8M
GMAB icon
17
Genmab
GMAB
$19.5B
$1.83M 0.19%
+50,000
New +$1.81M
MOR
18
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-95,898
Closed -$3.04M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Aquilo Capital Management held 18 positions worth $945M, up 90% from $496M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Aquilo Capital Management deployed $500M of net new capital in Q3 2020, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Dianthus Therapeutics: 59,914 shares worth $6.52M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 47% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $6.8M trimmed.

  • Aquilo Capital Management's largest Q3 2020 buy was Dianthus Therapeutics: 59,914 shares worth $6.52M.
  • Aquilo Capital Management added most to Spero Therapeutics in Q3 2020, an estimated $30.2M increase.
  • Aquilo Capital Management's biggest Q3 2020 reduction was argenx, cutting an estimated $6.8M.
  • Aquilo Capital Management fully exited MorphoSys AG American Depositary Shares in Q3 2020, selling an estimated $3.04M.
  • Aquilo Capital Management's ten largest holdings make up 96% of its $945M portfolio in Q3 2020.
  • Aquilo Capital Management opened 4 new positions and closed 1 in Q3 2020.
  • Aquilo Capital Management's portfolio value rose 90% quarter-over-quarter to $945M.

Based on Aquilo Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.